Ann: Appendix 4D Half Yearly Report and Accounts, page-3

  1. 952 Posts.
    lightbulb Created with Sketch. 139
    For those that missed it in the H1, probably the most pertinent part:

    '...Strong news flow will continue in 2017 as we report on the clinical progress of CAVATAK as a potential new treatment in the fast-growing field of cancer immunotherapy.'

    Bring it on...

    Good buying opportunity atm, in my opinion...

    ML
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.